This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LumiraDx Temettü

Temettü kriter kontrolleri 0/6

LumiraDx şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.94
Gelecekteki Temettü Verimi	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

Dec 20

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Apr 17

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

Nov 16

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Aug 20

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

Aug 18

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Jul 15

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LMDX.F şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LMDX.F şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

LumiraDx Piyasaya Karşı Temettü Getirisi

LMDX.F temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LMDX.F)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (LMDX.F) (3 yıla kadar)	n/a

Önemli Temettü: LMDX.F şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LMDX.F şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LMDX.F şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LMDX.F herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

This company listing is no longer active

LumiraDx Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

Nasdaq to Delist Common Stock of LumiraDx Limited

LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index

LumiraDx Announces Its Securities To Be Suspended from Trading on Nasdaq At the Open of Business on January 9, 2024

Nasdaq to Suspend Trading of LumiraDx's Securities and to File Form 25-NSE with SEC

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer

LumiraDx Announces Receipt of Nasdaq Delisting Determination, Plans to Appeal

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Executive Changes

LumiraDx Limited to Report Q2, 2023 Results on Aug 24, 2023

Insufficient new directors

LumiraDx Limited to Report Q1, 2023 Results on May 16, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Price target decreased by 12% to US$1.83

Consensus revenue estimates decrease by 51%, EPS upgraded

Price target decreased by 29% to US$2.49

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

Lumiradx Receives FDA Emergency Use Authorization and UK CTDA Approval for Its Fast Lab Solutions Multiplex Covid and Influenza Molecular Assay

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LumiraDx Limited Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

LumiraDx Limited, Annual General Meeting, Dec 15, 2022

Price target decreased to US$4.31

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Third quarter 2022 earnings: Revenues exceed analyst expectations

LumiraDx Limited to Report Q3, 2022 Results on Nov 09, 2022

LumiraDx Partners with British in Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Consensus EPS estimates fall by 25%

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Price target decreased to US$6.38

Second quarter 2022 earnings: Revenues miss analyst expectations

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

LumiraDx Limited to Report Q2, 2022 Results on Aug 18, 2022

Investor sentiment deteriorated over the past week

LumiraDx Limited has completed a Follow-on Equity Offering in the amount of $75.25 million.

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Investor sentiment deteriorated over the past week

Price target decreased to US$7.63

Price target decreased to US$8.00

Investor sentiment deteriorated over the past week

LumiraDx Limited Expands Its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

LumiraDx Limited Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

Consensus EPS estimates fall by 72%

Price target decreased to US$9.75

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.56

Consensus EPS estimates fall by 75%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q4, 2021 Results on Mar 10, 2022

LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete

Consensus EPS estimates increase by 96%

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx Limited Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions

Third quarter 2021 earnings released: EPS US$0.63 (vs US$0.82 loss in 3Q 2020)

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin